T1	Participants 447 480	newly diagnosed multiple myeloma.
T2	Participants 612 650	314 of 604 patients had been enrolled.
T3	Participants 663 727	598 patients who received at least one dose of trial medication.
T4	Participants 776 820	patients treated with intravenous bortezomib
T5	Participants 928 972	patients treated with intravenous bortezomib
